Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779034 | 0.80 | HPGD (0.72) | HPGDRECQLCA1CA2NHERF1 | |
| SCHEMBL10809740 | 0.79 | HPGD (1.00) | HPGDCA1CA2ALDH1A1LMNA | |
| SCHEMBL7821508 | 0.78 | HPGD (0.67) | HPGDRECQLCA1CA2NHERF1 | |
| SCHEMBL4031960 | 0.76 | HPGD (0.58) | HPGDRECQLCA1CA2NHERF1 | |
| SCHEMBL1020558 | 0.75 | HPGD (1.00) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL6526759 | 0.74 | HPGD (0.69) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL18873305 | 0.74 | HPGD (0.69) | HPGDRECQLCA1CA2ALDH1A1 | |
| SCHEMBL6518780 | 0.73 | HPGD (0.67) | HPGDRECQLCA1CA2ALDH1A1 | |
| Hydrazine SCHEMBL28785858 | 0.73 | CA1 (0.75) | HPGDRECQLCA1CA2NHERF1 | |
| SCHEMBL4753529 | 0.72 | HPGD (1.00) | HPGDRECQLCA1CA2NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594497-B1 | SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERTEX PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7432292-B2 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-07 | — | — | US | disclosed |
| US-20040167187-A1 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167187-A1 | Sulfhydantoins as phosphate isosteres | PTPN2, PTPRS, DUSP2 | HPGD 1779/4885RECQL 479/4885CA1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.